{"url_path":"/sec/adtx/8-k/2026-06-01/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1726711/0001213900-26-063165-index.html","accession_number":"0001213900-26-063165","cik":"0001726711","ticker":"ADTX","issuer_name":"Aditxt, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1726711/0001213900-26-063165-index.html","primary_entity_key":"0001726711","primary_entity_name":"Aditxt, Inc."},"word_count":622,"has_tables":true,"body_markdown":"**Item 5.02. Departure of Directors or Certain Officers; Election\nof Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**\n\n** **\n\n**Resignation of Chief Executive Officer and Director – Amro\nAlbanna**\n\n \n\nOn May 29, 2026, Amro Albanna notified the Company of his decision\nto resign as Chief Executive Officer of Aditxt, Inc. (the “Company”), and on May 30, 2026, Mr. Albanna resigned as a member\nof the Company’s Board of Directors (the “Board”), effective immediately. On May 31, 2026, the Board accepted Mr. Albanna’s\nresignation as Chief Executive Officer, effective as of such date. Mr. Albanna’s resignation as a director was not the result of\nany disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.\n\n** **\n\n**Resignation of Director – Shahrokh Shabahang**\n\n \n\nOn May 31, 2026, Shahrokh Shabahang resigned as a member of the Board,\neffective immediately. Dr. Shabahang’s resignation was not the result of any disagreement with the Company on any matter relating\nto the Company’s operations, policies, or practices. Dr. Shabahang continues to serve as the Company’s Chief Innovation Officer.\n\n** **\n\n**Resignation of Chief Operating Officer – Rowena Albanna**\n\n \n\nOn May 31, 2026, Rowena Albanna notified the Company of her decision\nto resign as Chief Operating Officer of the Company, effective June 5, 2026.\n\n** **\n\n**Appointment of Interim Chief Executive Officer – Jeffrey\nM. Busch**\n\n \n\nOn May 31, 2026, the Board appointed Jeffrey M. Busch, age 68, to serve\nas Interim Chief Executive Officer of the Company, effective as of such date.\n\n \n\nMr. Busch has served as Chief Executive Officer of Ignite Proteomics\nLLC, a wholly owned subsidiary of the Company, since March 2026. From June 2014 to June 2025, Mr. Busch served as Founder, Chairman and\nChief Executive Officer of Global Medical REIT Inc. (NYSE: GMRE), a healthcare real estate company that he founded and took public on\nthe New York Stock Exchange. Since 1999, Mr. Busch has also served as Founder, President and Chief Executive Officer of Safe Blood International\nFoundation, a global public health organization. Over the course of more than three decades, Mr. Busch has held director and senior executive\nroles across a number of biotechnology, diagnostics, and medical technology companies, and previously held two U.S. presidential appointments,\nincluding service as a United States Delegate to the United Nations in Geneva and as Assistant to the Secretary of the U.S. Department\nof Housing and Urban Development. Mr. Busch holds a J.D. from Emory University School of Law and an M.P.A. and a B.S. in Business from\nNew York University.\n\n \n\nThere are no arrangements or understandings between Mr. Busch and any\nother person pursuant to which he was appointed as Interim Chief Executive Officer. There are no family relationships between Mr. Busch\nand any director or executive officer of the Company. There are no transactions, or proposed transactions, to which the Company is or\nwas a participant and in which Mr. Busch has a material interest that would be required to be disclosed pursuant to Item 404(a) of Regulation\nS-K.\n\n \n\nIn connection with his appointment as Interim Chief Executive Officer,\nthe Company intends to enter into an interim employment arrangement with Mr. Busch providing for an annual base salary of $500,000. The\nmaterial terms of such arrangement had not been finalized as of the date of this Current Report on Form 8-K. The Company will file an\namendment to this Current Report on Form 8-K containing the information required by Item 5.02(c)(3) within four business days after the\nmaterial terms of Mr. Busch’s compensatory arrangement are determined.\n\n \n\n**Appointment of Chairman of the Board – Brian Brady**\n\n \n\nOn May 31, 2026, the Board appointed Brian Brady, an independent director\nof the Company, to serve as non-executive Chairman of the Board, effective as of such date.\n\n \n\n1"}